Source:http://linkedlifedata.com/resource/pubmed/id/18519679
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
2008-6-3
|
pubmed:abstractText |
Mel-18, a polycomb group (PcG) protein, has been suggested as a tumor suppressor in human breast cancer. Previously, we reported that Mel-18 has antiproliferative activity in breast cancer cells. However, its functional mechanism has not been fully elucidated. Here, we investigated the role of Mel-18 in human breast cancer. We saw an inverse correlation between Mel-18 and phospho-Akt, which were expressed at low and high levels, respectively, in primary breast tumor tissues from 40 breast cancer patients. The effect of Mel-18 on cell growth was examined in two breast cancer cell lines, SK-BR-3 and T-47D, which express relatively low and high levels of endogenous Mel-18, respectively. On Mel-18 overexpression in SK-BR-3 cells, cell growth was attenuated and G(1) arrest was observed. Likewise, suppression of Mel-18 by antisense expression in T-47D cells led to enhanced cell growth and accelerated G(1)-S phase transition. In these cells, cyclin-dependent kinase (Cdk)-4 and Cdk2 activities were affected by Mel-18, which were mediated by changes in cyclin D1 expression and p27(Kip1) phosphorylation at Thr(157), but not by INK4a/ARF genes. The changes were both dependent on the phosphatidylinositol 3-kinase/Akt signaling pathway. Akt phosphorylation at Ser(473) was reduced by Mel-18 overexpression in SK-BR-3 cells and enhanced by Mel-18 suppression in T-47D cells. Akt-mediated cytoplasmic localization of p27(Kip1) was inhibited by Mel-18 in SK-BR-3 cells. Moreover, Mel-18 overexpression showed reduced glycogen synthase kinase-3beta phosphorylation, beta-catenin nuclear localization, T-cell factor/lymphoid enhancer factor promoter activity, and cyclin D1 mRNA level. Taken together, we established a linear relationship between Mel-18-->Akt-->G(1) phase regulators.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinase Inhibitor...,
http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/PCGF2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-akt,
http://linkedlifedata.com/resource/pubmed/chemical/Repressor Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p14ARF
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1538-7445
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
1
|
pubmed:volume |
68
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
4201-9
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:18519679-Blotting, Western,
pubmed-meshheading:18519679-Breast Neoplasms,
pubmed-meshheading:18519679-Carcinoma, Ductal,
pubmed-meshheading:18519679-Cell Cycle,
pubmed-meshheading:18519679-Cell Line, Tumor,
pubmed-meshheading:18519679-Cyclin-Dependent Kinase Inhibitor p16,
pubmed-meshheading:18519679-DNA-Binding Proteins,
pubmed-meshheading:18519679-Down-Regulation,
pubmed-meshheading:18519679-Fluorescent Antibody Technique,
pubmed-meshheading:18519679-Humans,
pubmed-meshheading:18519679-Phosphorylation,
pubmed-meshheading:18519679-Proto-Oncogene Proteins c-akt,
pubmed-meshheading:18519679-Repressor Proteins,
pubmed-meshheading:18519679-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:18519679-Tumor Suppressor Protein p14ARF
|
pubmed:year |
2008
|
pubmed:articleTitle |
Mel-18 negatively regulates INK4a/ARF-independent cell cycle progression via Akt inactivation in breast cancer.
|
pubmed:affiliation |
Department of Pathology, College of Medicine, Hanyang University, Seoul, Republic of Korea.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|